NCT03198923UnknownPhase 1
A Phase 1/2 Safety and Efficacy Study of Natural Killer and Natural Killer T Cell Immunotherapy in Patients With Non Small Cell Lung Cancer
Wenxiang Wang1 site in 1 country30 target enrollmentStarted: September 13, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Overall Survival (OS)
Study Overview
Brief Summary
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung cancer.
Detailed Description
With the development of oncology and immunology in recent years, immunotherapy represents a novel path to obtain a durable and long-lasting response in cancer patients. NK and NKT cells are expanded conventionally from peripheral blood mononuclear cells by addition of a variety of cytokines in vitro culture. Our previous studies demonstrated that the expansion of NK and NKT cells in a clinical usage scale from peripheral blood mononuclear cells is feasible. Those expanded NK and NKT cells exhibit antitumor effect in vitro and in vivo against a variety of tumor cells. The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 4 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 3 year.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age: 18 to 75 years, Male or Female
- •Histological or cytologically diagnosis of non-small cell lung cancer
- •Recurrent or metastatic after surgical treatment
- •The pathology must be an assessable disease, signal lesion not exceeding 3 cm in diameter (measurable by CT scan or MRI)，number of Lymph node metastasis is less than 5
- •Refractory to standard treatments (e.g., chemotherapy, radiation, etc.)
- •No chemotherapy and radiation therapy to be planned recently
- •Patients must have a Karnofsky performance status greater than or equal to 70%
- •Life expectancy greater than 3 months
- •Able and willing to give witnessed, written informed consent form prior to receiving any study related procedure
- •Agree that progress of the disease must be radiographically measurable by computerized tomography (CT) scanning technique or magnetic resonance imaging (MRI) (per RECIST1.1 criteria)
- •Agrees to participate in long-term follow-up for up to 3 years, if received NK and NKT infusion
- •Laboratory values within the following ranges prior to receiving treatment of study agent: Peripheral blood cells >3×10^9 /L; Number of lymphocytes >1.0×10^9 /L; Lymphocyte ratio >18%; INR<1.5.
Exclusion Criteria
- •Patients with no surgical treatment
- •Patients within concurrent chemotherapy or radiation
- •Known or suspected allergy to the investigational agent or any agent given in association with this trial
- •Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C PCR within 21 days prior to enrollment
- •History of immunodeficiency disease or autoimmune disease
- •Patients with chronic disease which is undergoing immune reagents or hormone therapy
- •Serious infections requiring antibiotics, bleeding disorders
- •Previous bone marrow or stem cell transplant, or organ allograft
- •Concurrent other medical condition that would prevent the patient from undergoing protocol-based therapy
- •Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent
- •Pregnant or breast-feeding patients
- •Lack of availability of a patient for immunological and clinical follow-up
Outcomes
Primary Outcomes
Overall Survival (OS)
Time Frame: Approximately 3 years
The incidence of adverse events following infusion of NK and NKT cells
Time Frame: 30 days post-infusion
Secondary Outcomes
- Objective Response Rate (ORR)(up to 24 weeks)
- Tumor Marker(up to 24 weeks)
- Progression-Free Survival (PFS)(Approximately 1 years)
Investigators
Wenxiang Wang
Professor
Hunan Province Tumor Hospital
Study Sites (1)
Loading locations...
Similar Trials
Suspended
Phase 1
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on CancerHepatocellular CancerSquamous Cell Lung CancerBreast CancerProstate CancerPancreatic CancerColon CancerGliomaNCT00909558Envita Medical Center, Inc.24
Completed
Phase 1
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerAggressive Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaPreviously Treated Myelodysplastic SyndromeRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Indolent Adult Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRecurrent Plasma Cell MyelomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaAcute Myeloid LeukemiaRefractory Plasma Cell MyelomaRefractory Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaAcute Lymphoblastic LeukemiaNCT00789776Fred Hutchinson Cancer Center41
Unknown
Phase 1
NK Cells Infusion for Advanced MalignanciesImmunotherapyNCT03619954Anhui Provincial Hospital50
Completed
Phase 1
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Gene MutationsBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positivede Novo Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveTherapy-Related Acute Myeloid LeukemiaMyelodysplastic SyndromeNCT01904136M.D. Anderson Cancer Center54
Completed
Phase 2
Natural Killer (NK) Cell Therapy in Locally Advanced HCCLocally Advanced Hepatocellular CarcinomaNCT05040438Vaxcell Bio, Co., Ltd.17